Information Provided By:
Fly News Breaks for January 9, 2020
ICPT, TGTX, NGM, ARWR, AGEN, DRNA, ABUS
Jan 9, 2020 | 08:49 EDT
B. Riley FBR analyst Mayank Mamtani raised his price target for Arbutus Biopharma (ABUS) to $6 from $3 and keeps a Buy rating on the shares. In a research note detailing biotech catalysts in the first half of 2020, the analyst says Arbutus, along with Agenus (AGEN), Arrowhead (ARWR), NGM Biopharmaceuticals (NGM) and TG Therapeutics (TGTX) are his top five picks. HE also raised his price target for Buy-rated Dicerna Pharmaceuticals (DRNA) to $30 from $24 and Buy-rated Intercept Pharmaceuticals (ICPT) to $158 from $133.